Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents.

Détails

ID Serval
serval:BIB_9B840707F152
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents.
Périodique
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Auteur(s)
Wils P., Bouhnik Y., Michetti P., Flourie B., Brixi H., Bourrier A., Allez M., Duclos B., Grimaud J.C., Buisson A., Amiot A., Fumery M., Roblin X., Peyrin-Biroulet L., Filippi J., Bouguen G., Abitbol V., Coffin B., Simon M., Laharie D., Pariente B.
Collaborateur(s)
Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif
ISSN
1542-7714 (Electronic)
ISSN-L
1542-3565
Statut éditorial
Publié
Date de publication
02/2016
Peer-reviewed
Oui
Volume
14
Numéro
2
Pages
242-50.e1-2
Langue
anglais
Notes
Publication types: Journal Article ; Observational Study
Publication Status: ppublish
Résumé
Ustekinumab, a human monoclonal antibody against the p40 subunit of interleukins-12 and -23, is effective in inducing and maintaining remission in patients with luminal Crohn's disease (CD). We assessed the efficacy and safety of subcutaneous ustekinumab in patients with anti-tumor necrosis factor (anti-TNF) refractory CD.
We performed a retrospective observational study, collecting data from the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif on 122 consecutive patients with active CD refractory to anti-TNF therapy who received at least 1 subcutaneous injection of ustekinumab from March 2011 to December 2014, in 20 tertiary centers in Europe. Subjects were followed for at least 3 months. The primary outcome was clinical benefit, defined as reductions in symptoms and biochemical markers of CD and complete weaning from steroids, without surgery or immunosuppressant therapies.
Seventy-nine patients (65%) had a clinical benefit within 3 months of receiving ustekinumab. Concomitant immunosuppressant therapy at study inclusion increased the odds for a clinical benefit from ustekinumab (odds ratio, 5.43; 95% confidence interval, 1.14-25.77; P = .03). Over a median follow-up period of 9.8 months (interquartile range, 5.3-14.5 months), the cumulative probabilities that patients maintained the clinical benefit for 6 and 12 months after introduction of ustekinumab were 93% and 68%, respectively.
Almost two-thirds of patients with CD refractory to at least 1 anti-TNF agent receive clinical benefit from ustekinumab therapy, not requiring steroids for up to 12 months afterward. While awaiting results from ongoing trials, ustekinumab can be considered for use in these patients.

Mots-clé
Adult, Crohn Disease/drug therapy, Europe, Female, Humans, Immunologic Factors/adverse effects, Immunologic Factors/therapeutic use, Injections, Subcutaneous/adverse effects, Male, Retrospective Studies, Treatment Outcome, Tumor Necrosis Factor-alpha/therapeutic use, Ustekinumab/adverse effects, Ustekinumab/therapeutic use
Pubmed
Création de la notice
11/03/2016 12:10
Dernière modification de la notice
03/03/2018 19:54
Données d'usage